A Randomized, Placebo-controlled, Double-blind Study to Investigate the Effects of the Tyrosine Kinase Inhibitor Imatinib on Pulmonary Vascular Dysfunction in a Human Experimental Model of Acute Lung Injury
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2018
At a glance
- Drugs Imatinib (Primary)
- Indications Acute lung injury
- Focus Therapeutic Use
- Sponsors Exvastat
- 12 Jul 2018 Status changed from recruiting to completed.
- 14 Nov 2017 Status changed from not yet recruiting to recruiting.
- 06 Nov 2017 New trial record